{"filing":{"accession_number":"0001434265-26-000100","cik":"0001434265","ticker":"GNMSF","company_name":"GENMAB A/S","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"gmab_20260629x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434265/000143426526000100/gmab_20260629x6k.htm"},"events":[{"id":14658,"run_id":13060,"accession_number":"0001434265-26-000100","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This is a company announcement of positive Phase 3 clinical trial results for epcoritamab (EPCORE DLBCL-4), demonstrating statistically significant improvement in progression-free survival. While the announcement discloses clinical development progress rather than financial results, regulatory approval, or a discrete corporate event, the positive Phase 3 data for a key pipeline asset in a major indication (relapsed/refractory DLBCL) represents material operational/strategic progress that would affect a reasonable investor's assessment of the company's pipeline value and commercial prospects. This is classified as operational_other because it is clearly an operational/strategic milestone (clinical trial success) that does not fit the earnings_release category (which is for financial results) or other specific event types.","company_name":"GENMAB A/S","ticker":"GNMSF","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":12151,"accession_number":"0001434265-26-000100","item_number":"EX-99.1","item_title":"gmab_20260629xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a company announcement of positive Phase 3 clinical trial results for epcoritamab (EPCORE DLBCL-4), demonstrating statistically significant improvement in progression-free survival. While the announcement discloses clinical development progress rather than financial results, regulatory approval, or a discrete corporate event, the positive Phase 3 data for a key pipeline asset in a major indication (relapsed/refractory DLBCL) represents material operational/strategic progress that would affect a reasonable investor's assessment of the company's pipeline value and commercial prospects. This is classified as operational_other because it is clearly an operational/strategic milestone (clinical trial success) that does not fit the earnings_release category (which is for financial results) or other specific event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:24:38.799878+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12151,"accession_number":"0001434265-26-000100","item_number":"EX-99.1","item_title":"gmab_20260629xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a company announcement of positive Phase 3 clinical trial results for epcoritamab (EPCORE DLBCL-4), demonstrating statistically significant improvement in progression-free survival. While the announcement discloses clinical development progress rather than financial results, regulatory approval, or a discrete corporate event, the positive Phase 3 data for a key pipeline asset in a major indication (relapsed/refractory DLBCL) represents material operational/strategic progress that would affect a reasonable investor's assessment of the company's pipeline value and commercial prospects. This is classified as operational_other because it is clearly an operational/strategic milestone (clinical trial success) that does not fit the earnings_release category (which is for financial results) or other specific event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:24:38.799878+00:00","company_name":"GENMAB A/S","ticker":"GNMSF","filing_date":"2026-06-29"}]}